The antiatherosclerotic effects of a calcium channel blockers have been attracting attention for some time. It is shown by the animal studies that especially dihydropyridine calcium channel blockers have the antiatherosclerotic effects by an anti-oxidative properties and the direct action on vascular cells in addition to an original decrease blood pressure, and the validity is being further proved by the results of randomized clinical trials such as PREVENT and CAMELOT.